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Background: Degos disease is a frequently fatal and incurable occlusive vasculopathy most commonly affecting
the skin, gastrointestinal tract and brain. Vascular C5b-9 deposition and a type I interferon (IFN) rich microenviron-
ment are held to be pathogenetically important in the evolution of the vascular changes. We recently discovered
the use of eculizumab as a salvage drug in the treatment of near fatal Malignant atrophic papulosis (MAP). The ef-
fects of eculizumab on the pathology of MAP are explored.
Methods: Archival skin and gastrointestinal biopsy material was procured over a 2.5-year period before and after
eculizumab therapy in our index case. Routine light microscopy and immunohistochemical assessment for C3d,
C4d, C5b-9, MxA and caspase 3 were examined. Direct immunofluorescent studies were also conducted on select
biopsy material.
Results: The patient had received eculizumab as a emergent life saving measure and following rapid improvement he
continued with biweekly infusions for 4 years. Although improved he continues to have signs and symptoms of
persistent abdominal disease. Pre-Eculizumab biopsies showed an active thrombotic microangiopathy associated with
a high type I interferon signature and extensive vascular deposits of C5b-9 in skin and gastrointestinal biopsies.
Endothelial cell apoptosis as revealed by Caspase 3 expression was noted. Inflammation comprising lymphocytes and
macrophages along with mesenchymal mucin was observed as well. Post-eculizumab biopsies did not show active
luminal thrombosis but only chronic sequelae of prior episodes of vascular injury. There was no discernible caspase 3
expression. After 12 months of therapy, C5b-9 was no longer detectable in tissue. The high type I IFN signature and
inflammation along with mucin deposition was not altered by the drug. In addition, there was little effect of the drug
on the occlusive fibrointimal arteriopathy which appears to be one characterized by extensive myofibroblastic
expansion of the intima potentially as revealed by staining for smooth muscle actin without immunoreactivity for
desmin and myogenin.
Conclusions: Complement activation and enhanced endothelial cell apoptosis play an important role in the
thrombotic complications of MAP. However, the larger vessel proliferative intimal changes appear to be independent
of complement activation and may be on the basis of other upstream mechanisms. Monitoring C5b-9 deposition in
tissue is likely not of great value in assessing treatment response to eculizumab given the persistence of C5b-9 in tissue
for several months despite clinically effective C5 blocking therapy. A more integrated approach addressing upstream
and downstream pathways in addition to those attributable to complement activation are critical for the
successful treatment of MAP. Eculizumab may be used as salvage therapy in critically ill patients with
thrombotic microangiopathy.
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Malignant atrophic papulosis (MAP) falls under the alter-
native appellation of Degos disease and Kohlmeier-Degos
disease [1-3]. It is a severe and frequently progressive
angiopathy syndrome targeting certain organs, most com-
monly the skin, gastrointestinal tract, and central nervous
system, although other organ sites including the lung and
heart can be involved [4-6]. This syndromic complex has
very distinctive cutaneous lesions characterized by depres-
sed porcelain plaques with an atrophic center. Similar
lesions can affect the gastrointestinal tract as well.
There are two fundamental components to the vascular
disease in MAP, namely a thrombotic microangiopathy
targeting capillaries and venules, and a strangulating fi-
brointimal arteriopathy involving small and medium-sized
arteries [7]. The thrombotic microangiopathy affecting
capillaries and venules is most commonly manifested in
the skin and is the pathogenetic basis of the characteristic
cutaneous porcelain plaques. Nevertheless, a thrombotic
microangiopathy can affect any organ system and produce
acute ischemic symptoms analogous to other catastrophic
thrombotic microangiopathy syndromes such as anti-
phospholipid antibody syndrome, thrombotic thrombocy-
topenic purpura and hemolytic uremic syndrome [8,9]. In
contradistinction, a significant component of the gastro-
intestinal pathology is attributable to the larger vessel
fibrointimal arteriopathy of the submucosal vessels and
serosa. Similar arteriopathic changes affect other or-
gans, most notably the subdural arteries and coronary
vasculature.
We have shown in previous studies that there is a role
for both type I interferons as well as C5b-9 in the evolu-
tion of the microangiopathy and larger vessel arteriopathic
changes that define MAP [7]. Human Myxovirus resis-
tance protein 1 (MxA), a widely recognized and accepted
marker of type I interferon bioactivity, is highly expressed
in MAP, and its expression parallels the pattern of C5b-9
deposition [7]. Due to the extent of membranolytic attack
complex deposition within the cutaneous vasculature, we
previously hypothesized that blocking C5 through the ad-
ministration of eculizumab could potentially halt disease
progression and possibly even offer a cure to this once
fatal disease. We discovered that the drug has a beneficial
effect in catastrophic presentations of MAP. However, pa-
tients continued to experience symptoms related to the
disease, especially in regards to gastrointestinal compli-
cations, indicative that the blocking of C5b-9, while sig-
nificantly beneficial and potentially life saving, does not
appear to be curative of MAP.
The purpose of this study is to better understand the
role of complement and, more specifically, C5b-9 (i.e.
the membranolytic attack complex) in the pathogenesis
of MAP. It is important to delineate more precisely the
sequelae of C5 blockage on the pathology of Degosdisease to appreciate both the beneficial effects and in-
herent limitations of the drug. We had the opportunity
to study multiple skin and gastrointestinal tissue samples
prior to the administration of eculizumab and for up to
two and a half years after the commencement of drug in
one patient.
Methods
Biopsy material was available from a patient with MAP
who has been receiving biweekly infusions of eculizumab
since October 2009. The tissues studied included skin,
small and large intestines, and pericardium. Specimens
available for assessment included those before and after
eculizumab therapy spanning a time period of July 2009 to
December 2011. In several cases, additional tissue was
available for immunofluorescent studies. The tissue was
analyzed with routine light microscopy and immunohisto-
chemical stains were performed to assess for deposition of
C5b-9, C3d, and C4d in tissue. In addition, the expression
of MxA was explored given the role of type I interferons
in the pathogenesis of the microangiopathy. To better
characterize the nature of the proliferative intimal re-
sponse, smooth muscle actin, desmin, myogenin, CD34,
and CD14 iimunohistochemical stains were conducted on
gastrointestinal resection specimens.
Immunohistochemical staining was performed on 4-μm-
thick, formalin-fixed, paraffin-embedded tissue sections by
using the Bond 3 Autostainer (Leica Microsystems, Buffalo
Grove, IL) and the Bond Polymer Refine detection system
(Leica Microsystems). Cleaved Caspase-3 (#9661, Cell
Signaling Technology, Boston, MA) was used at a dilution
of 1:50. C5b-9 (clone aE11, Dako, Carpinteria, CA) was
used at a dilution of 1:250. Antigen retrieval was performed
for Caspase-3 with Bond Epitope Retrieval Solution no. 1
(Leica Microsystems). Antigen retrieval for C5b-9 was
performed using Enzyme 1 from the Bond Enzyme Pre-
treatment Kit (Leica Microsystems). Immunostaining was
performed according to a modified manufacturer’s pro-
tocol and sections were counterstained with hematoxylin,
dehydrated, and embedded in Cytoseal XYL (Thermo
Scientific, Kalamazoo, MI).
Immunofluorescent studies were conducted on fresh fro-
zen tissue of the skin and gastrointestinal tract on selected
cases according to previously published protocols [6].
Results
Brief clinical synopsis
46-year-old male who initially presented with intermittent
abdominal cramping and non-bloody diarrhea in 2006. In
2007, he started to develop macule- and plaque-like le-
sions over his upper extremities and trunk. Despite a
negative lupus workup, he was given hydroxychloroquine
with transient mild subjective improvement in his abdom-
inal symptoms but no change in his skin lesions.
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with fever and abdominal pain of several days’ duration
and presented to our hospital. On a chest X-ray, he was
found to have sub-diaphragmatic free air as well as pleural
effusions. He was emergently sent to the operating room
(OR) for exploration. During surgery, he was found to
have scattered depressed whitish plaques on his colon and
small intestines, mirroring the gross morphology of the
skin lesions. A perforation was found in the terminal
ileum, which was resected. During this hospital stay, his
physical examination also revealed numerous hyperpig-
mented macules with central atrophy on the trunk and
extremities. A few erythematous papules with scaling in
the center on the neck and shoulders were also noted.
Skin biopsies of these lesions showed findings consistent
with Degos disease. The pathological features of the
resected small intestine and skin biopsies were discussed
below as pre-eculizumab changes. Post-surgery, the pa-
tient received intravenous immunoglobulin (IVIg) and
was discharged home on prohylactic-dose of low molecu-
lar weight heparin.
After discharge, he still experienced recurrent inter-
mittent episodes of abdominal pain. In September 2009,
he suffered another episode of severe abdominal pain He
was diagnosed of a partial small bowel obstruction. He
went to the OR and had lysis of adhesions. During sur-
gery, that his small intestine plaques related to MAP
seen at the first surgery appeared unchanged in number
and distribution.
In October 2009, he was admitted to the medical in-
tensive care unit (MICU) with left pleural and pericar-
dial effusions complicated by cardiac tamponade. A
thoracotomy performed with pericardial window chest
tube placement. A concomitant pericardium biopsy
showed changes consistent with MAP, the details of
which are discussed below as pre-Eculizumab pericar-
dium changes. His hospital stay was further complicated
by bilateral subsegmental pulmonary emboli and biven-
tricular failure with a left ventricular ejection fraction
(LVEF) of 17%. This rapid decline in his status
prompted the decision to initiate eculizumab treatment,
with simultaneous support care including Dobutamin,
Caspofungin for candida infection and Valganciclovir
for his cytomegaloviremia. He experienced significant
clinical improvement within 2–3 days of initiation of
treatment, and his LVEF increased to 57%. After receiv-
ing the initial 3 cycles of Eculizumab, the patient was
discharged home.
He continued eculizumab treatment as an outpatient
without complications. His symptoms remained stable
and he reported fewer new skin lesions in February 2010,
the patient was hospitalized again for small bowel obstruc-
tion and lysis of adhesions. The ostomy was resected and
the pathological findings are discussed below as post-eculizumab changes. Post surgery, he was found to have
peritonitis with proteinaceous ascites, and small bowel
wall thickening on imaging. A repeat skin biopsy was per-
formed in March 2010, which showed no significant active
endothelial cell necrosis. The findings of this and add-
itional follow-up skin biopsies are detailed below as post-
eculizumab changes. The patient’s symptoms again re-
solved with treatment and he was managed as an out-
patient with biweekly infusions of Eculizumab.
In July 2011, he developed walled-off sigmoid colon per-
foration unresponsive to medical therapy, for which he
underwent exploratory laparotomy with sigmoid colon
resection, mobilization of splenic flexure and diverting ile-
ostomy. Examination of the colon showed evidence of re-
mote perforation, and fibro-obliterative vascular changes
although without thrombosis and active vasculitis. The re-
sults are discussed in details below as the gastrointestinal
findings post-Eculizumab, along with results of the con-
comitant skin biopsies.
By the end of 2011, the patient had received 61 cycles of
eculizumab without complications, and had been largely
clinically stable. He continued to experience abdominal
pain; however, the pain is not severe and unaccompanied
by nausea or vomiting. His skin exam shows a few healed
scars along with scattered erythematous papules. However
the active inflammatory lesions have not undergo evolu-
tion into an atrophic porcelain white macule. In the last
year however he has had a progressively wasting course
due to persistent and progressive gastrointestinal disease.
Histologic results
We will review the biopsies sequentially and consider
two time points: before and after Eculizumab therapy.
Skin
Prior to eculizumab administration: An erythematous
lesion biopsied in July 2009 showed a thrombotic micro-
angiopathy with foci of vascular drop out (Figure 1A, 1B).
A scarred lesion was biopsied a few days later showed
fibrosis, epidermal thinning and vascular drop out. In both
biopsies prominent vascular deposition of C5b-9 (Figure 1C)
was noted along with extensive immunoreactant depo-
sition for MXA, the latter showing localization in the epi-
dermis, endothelium and inflammatory cells (Figure 1D).
There was focal nuclear staining of caspase 3 in the
endothelium.
Post Eculizumab administration. Subsequent to recei-
ving eculizumab, the patient underwent 6 sequential skin
biopsies 2 weeks to 25 months after commencing the drug.
In none of the post-eculizumab biopsies was there vascular
thrombosis (Figure 2A) but only changes reflective of ante-
cedent microvascular injury including subepidemal fibro-
sis, vascular drop out, vascular basement membrane zone
duplication and vascular ectasia (Figure 2A). A variable
Figure 1 A, B, C, and D: Skin histology pre-Eculizumab microvascular changes along with the pattern and extent of C5b-9 deposition
and MXA expression in tissue. An erythematous lesion biopsied in July 2009 shows a thrombotic microangiopathy along with dermal chronic
microvascular changes characterized by thickened basement membrane zones along with superficial vascular ectasia and foci of vascular drop
out. The chronic microvascular changes are present in both the A (200x) and B (1000x) biopsies while intraluminal fibrin deposition is noted in B.
(hematoxylin and eosin) In Figure 1A, there is a sparse perivascular lymphocytic infiltrate. The vessels appear hyalinized attributable to vascular
basement membrane zone reduplication. In Figure 1B, the vessel is largely devoid of endothelium and contains a loosely adherent thrombus. The
vessel is also noticeably thickened. Figure 1C exhibits the pattern of C5b-9 deposition pre-eculizumab. There is prominent deposition of C5b-9 by
immunofluroescence in the vessels in the pre-eculizumab biopsy (400x). Figure 1D demonstrates MxA in skin biopsy pre-Eculizumab. There is
extensive staining for MxA in the epidermis, endothelium and inflammatory cells in the pre-eculizumab biopsy indicative of a type I IFN rich
microenvironment (diaminobenzidene, 1000x).
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along with mucin deposition was present in post treat-
mentbiopsies (Figure 2B). High levels of MxA expression
similar to pretreatment biopsies was noted (Figure 2C).
C5b-9 both immunohistochemically and by immunofluo-
rescence was present for 8 months after commencing the
drug. Nine months after the commencement of the drug,
C5b-9 was no longer apparent (Figure 2D). The caspase 3
stains in all biopsies examined were essentially negative.
Gastrointestinal specimens
There were a total of 3 intestinal resection specimens
available for assessment. One was obtained prior to the
commencement of the drug (July 2009) and two were
procured 4 months (February 2010) and 21 months after
starting the drug (July 2011). There were aspects of the
pathology that was remarkably similar between the pre-
eculizumab specimen and the one obtained 21 months
after starting therapy. In both there was a striking or-
ganizing acute and chronic serositis compatible with a
recent perforation. An arteriopathy affected small and
medium-sized vessels of the submucosa and mesentery(Figure 3A and 3B respectively). In particular the vessels
showed a mucinous fibrointimal expansion and occlusion
by fibrous collagenous thrombi. The intima was focally in-
filtrated by macrophages There was extensive mesenchy-
mal mucin deposition within the submucosa accompanied
by a lymphocytic infiltrate Focal staining of endothelial
cells and interstitial cells (i.e. fibroblasts and inflammatory
cells) for caspase 3 in the pre-eculizumab resection spe-
cimens was observed although the caspase 3 stains fol-
lowing initiation of eculizumab were negative. There was
intense staining of endothelium, smooth muscle cells,
stromal cells and inflammatory cells for MxA in the before
and after eculizumab resection specimens. Immunohisto-
chemical assessment revealed marked deposition of C5b-9
in vessels of the submucosa in the pre-eculizumab speci-
men while the intestinal resection specimen procured 21
months after commencing therapy was devoid of endothe-
lial and intimal vascular staining (Figure 4A and 4B).
The resection specimen obtained 4 months after com-
mencing the drug showed an obliterative fibrointimal
arteriopathy without active vascular thrombosis C5b-9
were still detectable in tissue both by immunofluorescent
Figure 2 Skin microvascular changes and immunohistochemical assessment for C5b-9 and MXA staining post-eculizumab. A. Skin
histology post-eculizumab. Subsequent to receiving Eculizumab, the patient underwent 6 sequential biopsies 2 weeks to 25 months after commencing
the drug. In none of the post-eculizumab biopsies is there evidence of active endothelial cell injury and vascular thrombosis. A common finding in all
of the biopsies is one reflective of antecedent episodes of microvascular injury characterized by subepidemal fibrosis with vascular drop out, vascular
basement membrane zone duplication and vascular ectasia (diaminobenzidene, 200x). B. Inflammatory cell infiltrate in skin biopsy post-eculizumab.
A variable inflammatory cell infiltrate comprising lymphocytes and histiocytes primarily arranged around blood vessels is present in all of the biopsies.
The biopsy procured in March 2011, 16 months after the commencement of eculizumab, shows a striking lymphocytic and histiocytic infiltrate with
abundant mucin deposition. Despite the exuberant inflammation, active microvascular injury is not seen. In particular discernible vascular thrombosis is
not observed (hematoxylin and eosin, 400x). C. MxA in skin biopsy post-eculizumab. In all post-Eculizumab biopsies, there continues to be prominent
expression of MxA in the epidermis, inflammatory cells and endothelium (diaminobenzidene, 1000x). D. C5b-9 in skin biopsy post-eculizumab. Nine
months after the commencement of the drug, C5b-9 was no longer apparent (diaminobenzidene, 400x).
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after commencing the drug although at 5 months post
treatment an endoscopic biopsy was devoid of vascular
C5b-9 deposition.
Phenotypic assessment of the fibro-obliterative arteriopathy
Given the morphologic similarity between the arterio-
pathic changes in the pre-eculizumab specimen compared
to the post eculizumab specimens, we conducted pheno-
typic studies only on the post eculizumab gastrointestinal
resection specimen. The CD14 stain showed a striking in-
flux of CD14+ monocytes throughout the gastrointestinal
tract (Figure 5). In examining the diseased arteries, there
was a margination of monocytes to lie in apposition to the
adventitia with infiltration through the medial wall and ex-
tending into the intima; the cells exhibited a spindled
morphology (Figure 6). While the desmin extensively
highlighted the medial wall smooth muscle cells, the hy-
perplastic intima was essentially negative (Figure 7) A
similar result was seen with myogenin. Very extensivestaining was noted for smooth muscle actin. Staining was
not observed for CD34.
Other biopsies
In October 2009, the patient underwent a pleural biopsy
along with a pericardial biopsy, which was conducted
due to a large pericardial effusion. The pericardial biopsy
showed a thrombogenic vasculopathy with ischemic ne-
crosis accompanied by extensive vascular deposition of
C5b-9.
Discussion
We have presented a case of MAP in which the patient
received biweekly eculizumab infusions commencing in
October 2009. We have followed the patient’s clinical
course and as well performed sequential biopsies over a
2.5-year period, monitoring the effects of the drug on his
disease process from both a clinical and pathological per-
spective. As already alluded to, there are two aspects
to the vascular injury in MAP, one of which is likely
Figure 3 A and B: Submucosal vessels of intestinal resection
specimens pre- and post-eculizumab, respectively. There were a
total of 3 intestinal resection specimens available for assessment.
One was obtained prior to the commencement of the drug
(July 2009) and two were obtained 4 months (February 2010) and 21
months after starting the drug (July 2011). There are aspects of the
pathology that was remarkably similar between the pre-eculizumab
specimen and the one obtained 2 years after starting therapy. A striking
fibro-obliterative arteriopathy affects small and medium-sized vessels of
the submucosa as well as mesentery in both the pre- (A) and
post-treatment (B) resection specimens (3A, hematoxylin and eosin,
200x, 3B hematoxylin and eosin, 200x). In B, the intimal proliferative
changes are very striking comprising hypercellularity of the intima
along with an increase in intimal matrix represented by collagen and
hyaluronic acid.
Figure 4 A and B: C5b-9 in submucosal vessels of intestinal
resection specimens pre- and post-eculizumab, respectively.
Immunohistochemical assessment reveals marked deposition of
C5b-9 in vessels of the submucosa in the pre-eculizumab specimen
(A, diaminobenzidene, 400x) while the intestinal resection specimen
procured 21 months after commencing therapy (B, diaminobenzidene
400x) is devoid of vascular staining apart from nonspecific staining
within the elastic tissue of blood vessels.
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terized by a thrombotic microangiopathy affecting capil-
laries and venules whereby there is discernible endothelial
cell injury with endothelial cell detachment and resultant
vascular thrombosis. This microangiopathy is particularly
apparent in active skin lesions although it also plays a role
in the pathogenesis of the ischemic complications seen in
other organ sites such as the brain, gastrointestinal tract
and pericardium [1-3]. In addition part of the larger vessel
pathology is one reflective of a similar pattern of endothe-
lial cell injury and thrombosis.The drug has almost an immediate effect on ameliora-
ting small and larger vessel endothelial cell injury and vas-
cular thrombosis. These effects were morphologically
apparent after two doses of the drug, recognizing that the
symptoms that accompanied the catastrophic thrombotic
microangiopathy were improved significantly with the first
infusion of the drug. We postulate that the basis is likely
reflective of abrogation of endothelial cell apoptosis. While
caspase 3, an apoptosis marker, was discernible within the
endothelium of pre-eculizumab biopsies, a significant dec-
rement in caspase 3 expression was observed within a few
weeks of receiving the drug. There is literature precedent
regarding C5b-9 mediated endothelial cell apoptosis pri-
marily in the context of experimental models of glome-
rulonephritis [10]. We postulate that the deposition of
C5b-9 likely reflected complement activation triggered
directly by type I IFNs. There are a numbers of papers that
Figure 5 The CD14 stain shows a striking influx of CD14+
monocytes throughout the gastrointestinal tract with
margination of monocytes to lie in apposition to the
adventitia. Note the infiltration through the medial wall and
extension into the intima (diaminobenzidene, 200x).
Figure 7 In this section of artery, there is very extensive
staining for smooth muscle actin, an immunophenotypic
profile that is common in myofibroblastic cells of stem cell
hematopoietic and monocyte origin (diaminobenzidene, 200x).
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catalyst to the activation of complement and eventually to
C5b-9 deposition [11-15]. The high type I IFN signature
was revealed by the extensive staining of MxA within
endothelium and perivascular and interstitial inflamma-
tory cells.
A point worthy of mention concerns the persistence of
C5b-9 deposition for many months after the commence-
ment of the drug, reflecting the slow clearance of C5b-9
previously deposited in affected tissues. Hence monito-
ring C5b-9 deposition in tissue is likely not of great
value in assessing treatment response. From a morpho-
logic perspective, post-eculizumab skin biopsies did not
show active endothelial cell injury and/or thrombosisFigure 6 While the desmin extensively highlighted the medial
wall smooth muscle cells, the hyperplastic intima is essentially
negative indicative that the intimal cells are not of true medial
wall smooth muscle origin (diaminobenzidene, 200x).although more chronic change presumably on the basis
of prior episodes of thrombotic microvascular injury
may be quite impressive. Such changes include epider-
mal thinning, subepidermal fibrosis with vascular drop
out, compensatory vascular ectasia and vascular base-
ment membrane zone thickening.
In all of the biopsies, prominent MxA staining was
noted in endothelium, perivascular and interstitial inflam-
matory cells, and vascular smooth muscle. The excessive
type I IFN signature was not affected by eculizumab ad-
ministration. Activated macrophages exhibiting erythro-
cyte phagocytosis along with mucin deposition persisted
despite complement blockade, suggesting that its basis is a
direct sequela of IFNα production. However, the down-
stream events of frank endothelial cell apoptosis and
thrombosis within the vasculature appears to be halted by
the drug.
Our patient continued to have significant gastrointes-
tinal disease including peritonitis and bowel perforations
despite receiving biweekly infusions of the drug. In gastro-
intestinal tract specimens procured 4months and 2 years
after commencing the drug, there was persistence of the
fibromyxomatous intimal arteriopathy although without
vascular thrombosis. The segments of gut were resected
due to perforation. We hypothesized that the basis of the
perforation was one reflective of chronic and profound
ischemia due to progressive occlusive nonthrombotic fi-
brointimal arterial changes. The lack of overt small and or
larger vessel arterial thrombosis likely accounts for the ef-
ficacy of the drug in subverting catastrophic and likely
fatal ischemic events. However intimal atherosclerotic like
intimal narrowing although not specifically catastrophic
can lead to chronic nonfatal ischemic changes analogous
to the nonocclusive atherosclerotic narrowing operational
Magro et al. Orphanet Journal of Rare Diseases 2013, 8:185 Page 8 of 9
http://www.ojrd.com/content/8/1/185in chronic ischemic syndromes such as angina pectoris
and intermittent claudication. In this regard one might
surmise the drug may reduce mortality but the long term
morbidity of the disease remains. Currently our patient is
very unwell and is progressively wasting due to persistent
and likely progressive gastrointestinal disease.
There is now an emerging body of literature on the role
of type I IFN in the evolution of the atherosclerotic-like
larger vessel fibrointimal changes observed in patients
with systemic lupus erythematosus [8,9]. Patients with
lupus erythematosus display transitional upregulation of
the IFNα/interleukin-18 (IL-18) processing machinery
(a.k.a. the inflammasome) [16]. IL-18 has an inhibitory
effect on endothelial cell differentiation, leading to de-
creased vascular repair with enhanced large vessel vascular
injury Elevated levels of IL-18 also correlate with in-
creased intima and medial wall thickness [17,18]. It is
possible that the arteriopathy of MAP disease is pathogen-
etically very similar to the larger vessel arteriopathy of
systemic lupus erythematosus whereby pathways inde-
pendent of complement activation may be operational
[18]. A finding that is particularly intriguing in our case
was the massive infiltration of his gastrointestinal tract by
CD14+ monocytes which exhibited an unusual pattern of
arteriocentricity including their presence in the intima of
diseased vessels. Further characterization of the prolifera-
tive intima revealed marked staining for smooth muscle
actin although in the absence of staining for myogenin
and desmin. The phenotypic profile of the intima was one
compatible therefore with spindled cells showing CD14
positivity along with myofibroblastic differentiation. It is
well established that CD14+ monocytes exhibit conside-
rable plasticity and can undergo myofibroblastic differen-
tiation [19]. At least in this one case, the source of the
intimal myofibroblast, the putative cell responsible for
the hyperplastic intima, could ultimately be derived from
the surrounding CD14+ monocytes. The excessive num-
ber of CD14+ monocytes in the gastrointestinal tract may
reflect enhancement of monocyte recruitment triggered by
type I interferons. In addition under the influence of type I
interferons, CD14+ monocytes show enhanced expression
of sialic acid binding IgG lectin-1 binding (Siglec-1). In-
creased numbers of Siglec-1+ CD14+ monocytes has been
implicated in systemic sclerosis associated pulmonary
hypertension, systemic sclerosis [20,21], and coronary ar-
tery disease [22].
Conclusions
The drug eculizumab aborts the severe catastrophic
thrombotic microangiopathy events associated with Degos
disease, likely through antiapoptotic endothelial cell effects.
In this regard, the extent of thrombotic microangiopathic
and larger vessel alterations are significantly attenuated al-
though other deleterious sequelae associated with a type Iinterferon rich microenvironment such as endothelial
repair dysfunction and enhancement of CD14+ mono-
cyte influx with transdifferentiation into intimal myo-
fibroblasts remain unaltered.
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